Many great points! Thanks
The valuation you assigned of at least $100/Share sounds very reasonable Post-Merger but the question is when?
I don't anticipate this stock to immediately jump to that level although it would be wonderful. I do believe however that at some point in the near future the PPS will be a lot higher,IMO North of $250, but it will likely be bought out before then and continue to move UP!
My post was intended only as an interesting comparison to Cytodyn that shot UP from $0.26 to $10 within the past 52 weeks.
So the way I see it, ENZC will do A LOT better in our share price movement upward due to our superior Clone-3 Ab that clearly represents Disruption Biotechnology relative to HIV treatment and a host of other infectious disease viruses.
What we do know for certain is post Merger sky's the limit for the PPS with ENZC on track to out perform any comparative Biotech on the Stock Exchange!
Be well and prosper...